A rare case of poorly differentiated mixed neuroendocrine-nonneuroendocrine tumor of the caecum with long term survival: A case report

Endocr Regul. 2022 Oct 20;56(4):249-253. doi: 10.2478/enr-2022-0026. Print 2022 Oct 1.

Abstract

A 59-year-old woman presented with flushing attacks accompanied by tachycardia and hypotension, which lasted approximately 30 to 60 minutes, underwent 18 years ago a gastrointestinal tumor resection. The histologic examination revealed a poorly differentiated mixed neuroendocrine/adenocarcinoma located in the caecum with regional metastases. Postoperatively, the patient received combined chemotherapy of 5-fluorouracil with interferon for six months and since has remained asymptomatic. Her examination revealed positivity for chromogranin A (CgA) and a-Fetoprotein (aFP) (580 ng/24 h, normal range 27-94, and 10 IU/mL, normal range 0-6, respectively). Urinary 5-hydroxy indole acetic acid excretion was remarkably high (41.8 mg/24 h, normal range 2-10 mg/24 h). An abdominal Magnetic Resonance Imaging scan revealed multiple focal loci in the liver whose histological examination revealed a carcinoid tumor confirmed by an Octreoscan. Additional uptake was noted on the right shoulder and the right sternum-clavicle joint confirmed by Tc-99m MDP scan. The patient received somatostatin analogue therapy followed by long-acting release octreotide analogue therapy (30 mg/month) showing a partial improvement of relevant biomarkers. Two years later, carcinoid syndrome symptoms reappeared and due to the tumors expression of somatostatin receptors the patient received peptide receptor radionuclide therapy with 177Lu-DOTATATE that resulted in both clinical and biochemical improvements.

Keywords: MiNEN caecum carcinoid syndrome.

Publication types

  • Case Reports

MeSH terms

  • Cecum / metabolism
  • Cecum / pathology
  • Chromogranin A
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Interferons
  • Middle Aged
  • Neuroendocrine Tumors* / diagnostic imaging
  • Neuroendocrine Tumors* / drug therapy
  • Octreotide* / therapeutic use
  • Radioisotopes
  • Receptors, Somatostatin / metabolism
  • Somatostatin
  • Technetium Tc 99m Medronate
  • alpha-Fetoproteins

Substances

  • Octreotide
  • Receptors, Somatostatin
  • Chromogranin A
  • alpha-Fetoproteins
  • Technetium Tc 99m Medronate
  • copper dotatate CU-64
  • Somatostatin
  • Fluorouracil
  • Interferons
  • Radioisotopes